Dr. Carey on De-Escalating Treatments for Triple-Negative Breast Cancer

Lisa A. Carey, MD
Published: Monday, May 08, 2017



Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).

In the de-escalating realm, the use of neoadjuvant therapy is beneficial for minimizing the need for surgery, explains Carey. Data from non-randomized studies suggest that very small node-negative TNBC may not have much of a benefit from chemotherapy.

According to Carey, one of the hopes is the possibility of minimizing the use of anthracyclines. However, current data and prospective studies show that they still play a role in TNBC.
 
SELECTED
LANGUAGE


Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).

In the de-escalating realm, the use of neoadjuvant therapy is beneficial for minimizing the need for surgery, explains Carey. Data from non-randomized studies suggest that very small node-negative TNBC may not have much of a benefit from chemotherapy.

According to Carey, one of the hopes is the possibility of minimizing the use of anthracyclines. However, current data and prospective studies show that they still play a role in TNBC.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x